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Doxycycline-Induced Expression of
Transgenic Human Tumor Necrosis Factor  in
Adult Mice Results in Psoriasis-like Arthritis
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Nina Hamann,5 Anja Niehoff,5 Sven Hermann,6 Michel Eisenbla¨tter,3 Lydia Wachsmuth,3
Thomas Pap,3 Peter L. E. M. van Lent,7 Karin Loser,3 Johannes Roth,3 Frank Zaucke,8
Stephan Ludwig,1 and Viktor Wixler1
Objective. To generate doxycycline-inducible hu-
man tumor necrosis factor  (TNF)–transgenic mice
to overcome a major disadvantage of existing transgenic
mice with constitutive expression of TNF, which is the
limitation in crossing them with various knockout or
transgenic mice.
Methods. A transgenic mouse line that expresses
the human TNF cytokine exclusively after doxycycline
administration was generated and analyzed for the
onset of diseases.
Results. Doxycycline-inducible human TNF–
transgenic mice developed an inflammatory arthritis–
and psoriasis-like phenotype, with fore and hind paws
being prominently affected. The formation of “sausage
digits” with characteristic involvement of the distal
interphalangeal joints and nail malformation was ob-
served. Synovial hyperplasia, enthesitis, cartilage and
bone alterations, formation of pannus tissue, and in-
flammation of the skin epidermis and nail matrix
appeared as early as 1 week after the treatment of mice
with doxycycline and became aggravated over time. The
abrogation of human TNF expression by the removal
of doxycycline 6 weeks after beginning stimulation re-
sulted in fast resolution of the most advanced macro-
scopic and histologic disorders, and 3–6 weeks later,
only minimal signs of disease were visible.
Conclusion. Upon doxycycline administration, the
doxycycline-inducible human TNF–transgenic mouse
displays the major features of inflammatory arthritis. It
represents a unique animal model for studying the
molecular mechanisms of arthritis, especially the early
phases of disease genesis and tissue remodeling steps
upon abrogation of TNF expression. Furthermore,
unlimited crossing of doxycycline-inducible human
TNF–transgenic mice with various knockout or trans-
genic mice opens new possibilities for unraveling the
role of various signaling molecules acting in concert
with TNF.
Tumor necrosis factor  (TNF) is the prototype
of a proinflammatory cytokine that is mainly secreted by
activated macrophages, but also by keratinocytes, fibro-
blasts, and endothelial cells. It plays a key role in
activation of immune cells during the acute phase of
inflammation, but it also regulates fundamental cell
responses such as proliferation, differentiation, and ap-
optosis (1). When dysregulated, TNF displays several
pathologic activities resulting in the development of
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acute and chronic pathologies, among which psoriatic
arthritis (PsA) and rheumatoid arthritis (RA) are the most
prominent (2–4). In addition to attraction and activation
of immune cells, TNF also activates synovial fibroblasts,
keratinocytes, and osteoclasts, which in turn, secrete
further cytokines, chemokines, and alarmins, thus poten-
tiating a proinflammatory state and tissue damage.
Furthermore, the alarmins S100A8 and S100A9 have
been shown to act in a concerted manner with TNF.
S100A8 and S100A9 up-regulate TNF expression and
TNF up-regulates S100A8 and S100A9 expression in a
functional feedback loop, and both S100A8 and S100A9
are involved in induction of matrix metalloproteinases
(MMPs) (5,6), contributing significantly to inflamma-
tion, cartilage damage, and bone resorption (7–9).
Considering the great importance of TNF for
the induction and progression of arthritis, it is not
surprising that several mouse models overexpressing the
TNF cytokine have been established. The first was
generated by Keffer et al in 1991 (10). This transgenic
mouse contains the complete genomic sequence of the
human TNF gene. Only the 3-noncoding region was
replaced by the 3-untranslated region (3-UTR) of the
human -globin gene. These mice constitutively express
the human TNF cytokine and, 10 weeks after birth,
develop a severe form of RA that affects primarily ankle
joints. Other transgenic models soon followed. They
constitutively express either a human or a mouse TNF
transgene with a deleted or modified 3-UTR. These
transgenic mice, as well as the tristetraprolin-knockout
mouse, all developed arthritic diseases of differing se-
verity and allowed the deciphering of many molecular
details underlying their development (4,11). However,
TNF-transgenic mice usually also have impaired fertil-
ity (12). This dysfunction presents a serious hindrance in
crossing them with other animals to gain more insight
into the molecular mechanisms of arthritic diseases or
other disorders. To overcome this problem, we gener-
ated a doxycycline-inducible human TNF–transgenic
mouse (also called an ihTNFtg mouse) in which the
expression of the human TNF gene is under the control
of a tetracycline (Tet)–responsive promoter.
MATERIALS AND METHODS
Animal studies. The details of generating the
doxycycline-inducible human TNF–transgenic mouse are de-
scribed at http://zmbe.uni-muenster.de/vwixler/retser.zip. The
animals were maintained under pathogen-free conditions, and
all experiments were performed on mice homozygous for both
the Tg_rtTA2S transgene and the human TNF transgene.
Genotyping was performed with TaqMan quantitative reverse
transcription–polymerase chain reaction (qRT-PCR), using
genomic DNA from tail biopsy samples. To induce expression
of the human TNF transgene, 6-week-old mice were kept on
drinking water containing doxycycline (Sigma) and 5% sucrose
for the times indicated. The water was protected from light and
exchanged every 3 days.
Clinical assessments were performed weekly during the
doxycycline stimulation of the mice. Paw swelling was graded
from 0 to 3, and grip strength was graded from 0 to –3 as
previously described (13). The amount of human TNF cyto-
kine or mouse S100A8 and S100A9 proteins in the serum of
the mice was analyzed by enzyme-linked immunosorbent assay
(ELISA) as described previously (14).
In vivo imaging. Magnetic resonance imaging (MRI)
was performed with a 9.4T small animal MR scanner with a
helium-cooled Cryoprobe (Bio-Spec 94/20; Bruker BioSpin
MRI) and using ParaVision 5.1 software (Bruker BioSpin
MRI). Anesthetized mice were placed in the animal cradle in
a supine position with the fore limbs taped above the nose
cone. Isotropic 3-dimensional fast low-angle shoot sequence
images (repetition time 30 msec, echo time 4.2 msec, flip angle
15°, spatial resolution 52 m3) were acquired pre- and post-
bolus intravenous (IV) application of Magnevist (0.5 mmoles/
kg Gd; Bayer Healthcare). Total scan time per animal was
1 hour.
Leukocytes as a driving force of inflammatory pro-
cesses are highly glucose-avid, which allows the visualization of
local inflammation by 18F-fluorodeoxyglucose (18F-FDG).
Doxycycline-inducible human TNF–transgenic mice were in-
jected IV with 10 MBq 18F-FDG, and 1 hour later, a positron
emission tomography (PET) list-mode scan was performed for
15 minutes using a 32-module quadHIDAC scanner (Oxford
Positron Systems) dedicated to small animal imaging. The
scanner has an effective resolution of 0.7 mm (full width at
half maximum) in the transaxial and axial directions when
using an iterative resolution recovery reconstruction algo-
rithm. To noninvasively assess bone turnover, the distribution
of 99mTc-labeled methylene diphosphonate (MDP) was mea-
sured by single-photon–emission computed tomography
(SPECT) (NanoSPECT/CT; Mediso) 1 hour post–IV injection
of MDP.
High-resolution micro-CT scanning was performed
with a CT 35 scanner (Scanco Medical). Dissected fore paws
were scanned with an isotropic voxel size of 7 m, 70 kVp tube
voltage, 114 mA tube current, 200 msec integration time, and
frame averaging of 1. Distal interphalangeal (DIP) joints were
scanned with an isotropic voxel size of 3.5 m, 70 kVp tube
voltage, 114 mA tube current, 400 msec integration time, and
frame averaging of 2. A constrained Gaussian filter (support
2,   1.2) was used to remove noise in the original volume
data. Bone tissue was segmented using a global thresholding
algorithm (paws, 23.0% for 0 weeks doxycycline and 18.0% for
6 weeks doxycycline; DIP joints, 24.0% for 0 weeks doxycycline
and 19.0% for 6 weeks doxycycline).
RNA isolation, complementary DNA (cDNA) synthe-
sis, and TaqMan qRT-PCR. Mouse organs were collected,
minced, and immediately transferred into RNAlater solution
(Ambion). After overnight incubation at 4°C, they were ho-
mogenized, and the RNA was isolated by a Qiagen RNeasy kit.
The RNA integrity was controlled by a Bioanalyzer 2100
system (Agilent Technologies) and transcribed into cDNA
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using a high-capacity cDNA reverse transcription kit from
Applied Biosystems. Levels of messenger RNA (mRNA)
expression were determined by TaqMan qRT-PCR using a
LightCycler 480 II instrument (Roche Diagnostics). Each
cDNA probe was analyzed in triplicate, and specific signals
were scored in relation to the signals of 2 housekeeping gene
transcripts (GAPDH and cytochrome c). The results from
different experiments were normalized to the expression of a
calibrator probe, which was applied as a positive control in
each experiment. An intron region of the interleukin-2 (IL-2)
gene was always amplified to ascertain that the probes were
not contaminated with genomic DNA. The primers used were
assigned using the Universal ProbeLibrary Assay Design Cen-
ter (http://www.roche-applied-science.com/shop/CategoryDisplay
?catalogId10001&tab&identifierUniversalProbeLibrary
&langId-1).
Histology and immunohistochemistry. The paws were
fixed overnight in 4% paraformaldehyde, decalcified with 0.5M
EDTA solution, and embedded in paraffin. Sections mea-
suring 4 m in thickness were analyzed. The extent of inflam-
mation and cartilage damage in the paws was determined by
morphometry as described elsewhere (13). Usually, 4 different
sections per mouse sample were quantified from 3–4 mice for
each time point. The inflamed area was defined as the infil-
trated tissue area and was assessed in relation to the total
tissue area (in toes, the area from the apex of a toe to the
proximal tendon basis of the DIP joints was defined as the
total area). Proteoglycan loss was determined as the percent-
age of destained cartilage area. For type II collagen detection,
specimens were sequentially digested with hyaluronidase and
proteinase K before incubation with the mouse anti–type II
collagen antibody (Merck). For its quantification, the stained
area was circumscribed and the relative stain intensity was
determined using Photoshop software (Adobe Systems). All
analyses were performed in a blinded manner by one of us
(ER, TS, or VW). For immunohistochemistry, paraffin sec-
tions were dewaxed, blocked with 10% fetal bovine serum,
and incubated with rabbit anti-S100A9 antibodies for 1 hour
at room temperature. A Vectastain ABC-AP Kit (Vector) was
used for visualization of the stained proteins.
Statistical analysis. Mean  SEM values were calcu-
lated, and statistical analysis was performed using the Mann-
Whitney U test and GraphPad Prism software. P values less
than 0.05 were considered significant.
RESULTS
Generation of doxycycline-inducible human
TNF–transgenic mice. The cDNA sequence for human
TNF was placed under the Tet-responsive promoter
and introduced into the pronuclei of FVB/N fertilized
mouse oocytes. The 3-UTR was replaced by an SV40
poly(A) site to avoid a posttranscriptional regulation
(see http://zmbe.uni-muenster.de/vwixler/retser.zip).
Two founders, called Tg_ihTNFF8 and Tg_ihTNFF15,
were then crossed with the Tg_rtTA2S-M2 mice (15),
kindly provided by Dr. John Strouboulis (Institute of
Molecular Oncology, Biomedical Sciences Research
Center, Varkiza, Greece). Southern blot analysis of
genomic DNA from F1 hybrids revealed unique but
different integration sites for the Tg_ihTNFF8 and
Tg_ihTNFF15 founders, with 4 and 5 tandem trans-
genic copies, respectively (see http://zmbe.uni-muenster.
de/vwixler/retser.zip). The F1 hybrid mice were further
intercrossed to obtain mice homozygous for both trans-
genes. The offspring of the Tg_ihTNFF15 founder
showed a typical Mendelian ratio and a normal life-
span, while those of the Tg_ihTNFF8 founder survived
only as heterozygotes, further confirming the noniden-
tical incorporation sites of the human TNF trans-
gene in the genomes of these 2 founders. The hetero-
zygous offspring of both founders showed no obvious
abnormalities without addition of doxycycline, but upon
treatment with the antibiotic, they developed a similar
phenotype. Thus, we focused the present study on
homozygous (Tg_rtTA2S//Tg_ihTNFF15/) mice,
named doxycycline-inducible human TNF–transgenic
mice (also called ihTNFtg mice).
Tissue expression pattern of human TNF tran-
scripts. Doxycycline-inducible human TNF–transgenic
mice homozygous for both human TNF and
rtTA2S-M2 transgenes received different amounts of
the antibiotic for 6 weeks, and the level of human TNF
in their sera was measured by ELISA in comparison
with that in non–doxycycline-treated mice. Detectable
levels of human TNF protein were identified only in
doxycycline-treated mice in a dose-dependent manner
(Figure 1A), although a particular variation between
single animals was observed as well. No soluble human
TNF cytokine could be detected in mice bearing only 1
of the transgenes (data not shown), confirming that the
presence of both transgenes and stimulation with doxy-
cycline are necessary for the expression of human TNF.
The alarmins S100A8 and S100A9 are calcium-
binding proteins that belong to the family of damage-
associated molecular pattern molecules, and they are
released by immigrating neutrophils and macrophages
very early during inflammation. They are increasingly
used as biomarkers for ongoing inflammatory processes,
especially for RA (16,17). The amount of S100A8/A9
heterodimer used as a biomarker to monitor inflamma-
tion was increased in the sera of the mice treated with
doxycycline, and the degree of elevation was dependent
on the amount of doxycycline the mice received (Figure
1B), suggesting that ongoing inflammation takes place in
doxycycline-treated mice and that the induced human
TNF is functionally active.
To study the expression pattern of the human
TNF transgene, different organs from doxycycline-
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stimulated mice were analyzed by TaqMan qRT-PCR in
comparison to different organs from untreated mice.
Upon administration of doxycycline, the synthesis of
human TNF mRNA was switched on in several organs,
with fore and hind paws showing the highest induction,
followed by skin, thymus, and lung (Figure 1C). The
degree of induction varied between individuals; how-
ever, the detected amounts of human TNF mRNA,
including the low scores, were specific and not due to
contamination of the RNA samples with genomic DNA.
The qRT-PCR counts for an intron sequence of the IL-2
gene were usually at least 2 orders of magnitude lower
than those of the TNF signals (data not shown). The
nontransgenic C57BL/6 wild-type mice treated with
doxycycline did not express any human TNF mRNA,
and the established double-transgenic mouse line
(doxycycline-inducible human TNF–transgenic mice)
showed only negligible levels of human TNF mRNA
when kept untreated.
Doxycycline-inducible human TNF–transgenic
mice develop polyarthritis. Long-term expression of
high TNF levels is associated with the development of
chronic inflammatory diseases, with RA being one of the
most prominent TNF-mediated disorders (10,12,18).
As the progression of arthritis is usually accompanied by
body wasting, swelling of joints, and movement impair-
ment, we analyzed the alteration of these parameters in
doxycycline-inducible human TNF–transgenic mice
during doxycycline application (Figures 1D and E and
2A). Mice bearing only 1 transgene (either the human
TNF transgene or the rtTA2S-M2 transgene) as well as
untreated double-transgenic mice did not show any
alterations. However, doxycycline-inducible human
TNF–transgenic mice showed the first macroscopic
Figure 1. Expression of human tumor necrosis factor  (hTNF) in doxycycline (Dox)–inducible human TNF–transgenic mice after doxycycline
administration. A and B, Systemic doxycycline-induced human TNF (n  8, 4, 9, and 6 mice for increasing concentrations shown) (A) and
S100A8/A9 proteins (n  6, 4, 5, and 6 mice for increasing concentrations shown) (B) in mouse serum, as determined by enzyme-linked
immunosorbent assay. C, Transcriptional expression of human TNF in tissues of untreated control mice and mice treated with doxycycline
(0.5 mg/ml for 6 weeks), as analyzed by TaqMan quantitative reverse transcription–polymerase chain reaction. The amount of mRNA in fore paws
of control mice was assigned a value of 1. Numbers of animals analyzed are shown above columns. D and E, Changes in body weight (D) and swelling
of fore paws (E) during stimulation with various concentrations of doxycycline (n  4 mice per time point for each group of mice). Values in A–E
are the mean  SEM.   P  0.01;   P  0.001 for doxycycline-treated mice versus untreated mice. F, Magnetic resonance imaging of
fore paws before and after injection of contrast agent (CA; 0.5 mmoles/kg) (n 5 mice per group). Arrowhead indicates prominent swelling of digits
after doxycycline treatment. Bar  1 mm. G, 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography imaging showing locally increased
18F-FDG uptake as a surrogate marker for inflammatory activity in distal interphalangeal joints of doxycycline-treated (arrowheads) (n  5 mice
per experiment) but not untreated (control; n  3 mice per experiment) doxycycline-inducible human TNF–transgenic mice. In addition, a typical
high uptake of the tracer by the heart and its excretion-based accumulation in the urinary bladder was always observed in both control
and doxycycline-treated mice. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/
art.38026/abstract.
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pathologies as early as 2 weeks after doxycycline admin-
istration. Swelling and redness of the fore and hind paws
along with diminished grip strength and reduced mobil-
ity appeared at that time and progressed constantly with
continuous doxycycline application. The severity of the
symptoms correlated with the amount of antibiotic ap-
plied, as did human TNF levels in sera.
Interestingly, ankle joints were not affected, un-
like the case with already-described human TNF–
transgenic mice with constitutive expression of the cyto-
kine (10,12), but the digits were strongly affected, and
fore paws were more strongly affected than hind paws.
Strong joint swelling and formation of so-called “sausage
digits” with almost characteristic involvement of the DIP
joints and nail deformation were very prominent. MR
imaging of fore paws at a spatial resolution of 52 m
revealed extensive swelling of the digits and edema of all
soft tissues in doxycycline-treated mice. After contrast
agent application (Figure 1F), all soft tissues exhibited
higher signal intensity. The observed features resembled
to a certain degree the signs of PsA. However, we
observed no plaque formation on the skin (which often
accompanies psoriasis), either on the digits or on other
parts of the body, although skin irritation with hair loss
on the head, neck, or ventral side often appeared (see
http://zmbe.uni-muenster.de/vwixler/retser.zip). No
other gross alterations or organ inflammation could be
detected when a whole-body PET imaging study was
performed using 18F-FDG (Figure 1G).
Development of arthritis in doxycycline-
inducible human TNF–transgenic mice is reversible.
To ascertain whether the observed phenotype was re-
versible, mice were stimulated for 6 weeks with
0.5 mg/ml doxycycline, after which the antibiotic was
removed. The grip strength improved continuously af-
ter the antibiotic was withdrawn (Figure 2A). Remark-
ably, 1 week after antibiotic withdrawal, transcription
of human TNF was barely detectable in the paws and
human TNF protein was barely detectable in the sera
of doxycycline-inducible human TNF–transgenic mice
(Figures 2B and C). While serum levels of human TNF
varied from 100 pg/ml to 1,300 pg/ml in mice treated for
Figure 2. Inflammation in paws of doxycycline-inducible human tumor necrosis factor  (hTNF)–transgenic mice is reversible. Six-week-old
doxycycline-inducible human TNF–transgenic mice received water with 0.5 mg/ml doxycycline for 6 weeks, after which they received water without
the antibiotic (weeks labeled 1 to 5). A, Changes in grip strength of hind paws during doxycycline treatment (n  4 mice for each time point).
B, Alteration in transcription of the human TNF transgene in paws (n  5, 5, 4, and 4 mice for the respective time points shown). C, Levels of
soluble human TNF cytokine in serum (n  4–9 mice at each time point). D, Fore paws of doxycycline-inducible human TNF–transgenic mice
before (0 weeks), during (6 weeks), and after (–5 weeks) doxycycline treatment. E, Histologic changes in toes of hind paws. Images of proximal
interphalangeal (PIP) joints are shown (toluidine blue staining). Note the progression of synovitis (asterisks), cartilage destaining (arrowheads), and
attachment and invasion of pannus-like tissue into bone (hatchmark). Bars  200 m. F and G, Histomorphometric quantification of inflamed
synovium (F) and cartilage loss of proteoglycan (G) in PIP joints shown in E (n  4 mice for each time point). Values are the mean  SEM.
  P  0.05;   P  0.01;   P  0.001.
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6 weeks, only 1 of the analyzed animals expressed fully
42 pg/ml human TNF 1 week after removal of the
antibiotic. Consistent with these data, macroscopic paw
symptoms also improved. Digit swelling was visibly re-
duced after doxycycline removal, and grip strength in-
creased progressively; after 3–5 weeks even screwed or
broken nails had recovered (Figure 2D).
We next performed histologic analyses of in-
flamed paws, concentrating our attention on the DIP
joints. Toluidine blue staining of paw sections revealed
the first signs of abnormalities as early as 1 week after
doxycycline treatment. Hyperplasia of synovial tissue
and infiltration by polymorphonuclear and lymphoid
cells into soft tissue and the joint space as well as
cartilage destruction (indicated by the destained pro-
teoglycan area) were evident. Particularly distinguishing,
however, was the high amount of pannus tissue, which
grew progressively with time and penetrated largely into
the bone tissue (Figure 2E). Morphometric quantifica-
tion of such inflammation and cartilage destaining
showed that these features increased with the duration
of doxycycline stimulation (Figures 2F and G). However,
withdrawing the antibiotic stopped the progression of
these abnormalities and induced gradual improvement,
which resulted in almost complete recovery 3 weeks
later.
DIP joints but not ankle joints are predomi-
nantly affected. In transgenic mice constitutively ex-
pressing TNF, ankle joints, but not digit joints, were
primarily affected (4,11). Therefore, we performed a
direct comparison of both joint types of the same hind
foot. Consistent with macroscopic observations, the toes
were more severely affected than the ankles, and the
DIP joints showed the greatest pathologic changes (Fig-
ure 3A). We measured 2–3-fold less cartilage destruc-
tion and erosion and 5–8-fold less pannus area in ankle
joints than in DIP joints (Figure 3B). Staining for
S100A9 protein as a marker of inflammation further
confirmed that the major inflammation process occurred
in the distal toes but not in the ankle regions of hind
Figure 3. Distal interphalangeal (DIP) joints but not ankle joints are severely inflamed in doxycycline-inducible human TNF–transgenic mice after
stimulation with doxycycline. Doxycycline-inducible human TNF–transgenic mice were treated with 0.5 mg/ml doxycycline for 6 weeks or left
untreated (control). A, Staining of serial sections of hind paws with toluidine blue (top) or antibodies to S100A9 protein (red) (bottom). Asterisks
indicate a strong synovitis in DIP joints but not ankle joints of doxycycline-treated mice. B, Quantification of inflammation (left), cartilage destaining
(middle), and cartilage erosion (right) by morphometry (n  4 mice per group).   P  0.01;   P  0.001 versus ankle joints. C, Expression
of human TNF transcripts in hind paw digits and ankles, quantified by TaqMan quantitative reverse transcription–polymerase chain reaction
(RT-PCR). Values for separate numbered animals are presented. D, Quantitative RT-PCR analysis of human TNF expression in the skin and the
rest of the tissues of hind paws (n  5 mice per group).   P  0.001. E, S100A9 staining (red) of a healthy skin section and an irritated (see
http://zmbe.uni-muenster.de/vwixler/retser.zip) skin section from a doxycycline-treated mouse. Nuclei (blue) were counterstained with hematoxylin.
F, Relationship between human TNF and interleukin-23 (IL-23) mRNA transcripts in skin samples from doxycycline-treated mice (n  12 mice).
  P  0.001. Bars  100 m. Values in B and D are the mean  SEM. See Figure 1 for other definitions.
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paws, as only weak staining for S100A9 was seen in the
ankle joint area (Figure 3A).
It is conceivable that the observed differences
between digits and ankles are based on different expres-
sion levels of human TNF in these organs. To assess
this possibility, we compared the expression of the
human cytokine in toes and ankles by qRT-PCR. As
shown in Figure 3C, digits indeed expressed much higher
levels of human TNF than did ankle structures, and the
induced cytokine was found predominantly in the skin
samples of paws but not in the rest of the tissues (Figure
3D). The high expression of human TNF in the skin
(Figures 1C and 3D) suggests an ongoing inflammatory
disorder in the organ, despite the absence of gross
macroscopic abnormalities. Indeed, the histologic ana-
lysis not only of the digit skin (Figures 3A and 4A), but
also of the irritated dorsal skin distal from toes (Figure
3E) showed clear signs of inflammation on doxycycline
induction, and the amount of human TNF mRNA
induced in dorsal, abdominal, or paw skin samples
correlated highly with levels of the cytokine IL-23 (Fig-
ure 3F), which is typically up-regulated during psoriasis
(19). The doxycycline per se, however, had only a minor,
if any, effect on the development of dermal inflam-
mation in nontransgenic mice (see http://zmbe.uni-
muenster.de/vwixler/retser.zip). It is worth mentioning
that besides the skin and paws, all other tissues and
joints analyzed, including the gut and the highly
“arthritis-sensitive” joints, such as the spine, sacroiliac,
and hip joints, were S100A9 negative and did not show
noteworthy morphologic alterations (see http://zmbe.
uni-muenster.de/vwixler/retser.zip).
Doxycycline-inducible human TNF–transgenic
mice develop onychia, psoriasis, and enthesitis. To
further define the structures in which inflammation
takes place in the DIP joints, paw sections of mice
stimulated for different amounts of time with doxycy-
cline were stained for S100A9 protein. While no staining
Figure 4. Inflammation in the toes of doxycycline-inducible human tumor necrosis factor –transgenic mice during (0–6 weeks) and after (weeks
labeled 1 to 3) doxycycline treatment, analyzed by S100A9 (red) expression. A, Immunohistochemistry of S100A9. Representative images of
S100A9-stained sections of hind paw toes are depicted. Note the inflammation of nail matrix (asterisks), chondrocytes (arrowheads), and bone tissue
(hatchmark). Bars  100 m. Samples were counterstained with hematoxylin to reveal nuclei (blue). Three to 5 animals per each time point were
analyzed. B and C, Changes in S100A8 (B) and S100A9 (C) transcripts in paws during doxycycline treatment, determined by TaqMan quantitative
reverse transcription–polymerase chain reaction (n  5 mice for each time point). Mean mRNA levels in untreated mice were assigned a value of
1. Values are the mean  SEM.
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was observed in doxycycline-untreated mice, strong
S100A9 staining was present as early as 1 week after
doxycycline addition. The staining intensity rose further
and remained during the whole time of doxycycline
stimulation. However, it dropped very quickly when the
antibiotic was removed (Figure 4A). The alteration in
S100A9 staining in paws correlated very well with tran-
scriptional induction of both S100A8 and S100A9 genes
(Figures 4B and C). Taken together, these data are
consistent with the morphometric analysis of inflamma-
tion and cartilage destruction shown in Figure 2. Fur-
ther, consistent with the results presented in Figures 2
and 3, only the phalanges showed strong staining for
S100A9 protein, with the DIP joint areas being the most
severely affected. Indeed, the more distant the joints
from the tips of the digits, the less S100A9 staining was
noted.
Among stained structures, skin, nail matrix, and
entheses were the most protruding (Figure 4A). Given
that a positive S100A9 signal indicates where inflamma-
tion takes place, induction of dermal inflammation,
onychia, and enthesitis of digit joints and especially of
DIP joints was most obvious. Again, the inflammation of
these organs was reversible, as it declined to the control
level shortly after ending doxycycline treatment, indicat-
ing that despite the strong induction of human TNF,
the disease did not turn into a chronic state with high
expression of endogenous inflammatory cytokines. In-
terestingly, keratinocytes of both the skin and nail matrix
were the cells with the highest expression of S100A9
protein. A serial-sections staining for S100A9 and pan-
keratin confirmed this observation (see http://zmbe.uni-
muenster.de/vwixler/retser.zip) and further showed that
not the actively proliferating parts of keratinocyte
sheets, but the more differentiated spinous layers were
highly positive for S100A9 protein. The staining was
seen very early after TNF induction and increased
further with ongoing doxycycline stimulation, indicating
an augmentation of inflammation in these tissues. Fur-
ther, the activation of nail matrix keratinocytes seemed
Figure 5. Alterations in gene expression are reversible. A and B, Immunostaining (left) and morphometric quantification (right) of type II collagen
(top) and tartrate-resistant acid phosphatase (TRAP) (bottom) in distal interphalangeal joints during (0–6 weeks) and after (weeks labeled 1 to
3) doxycycline stimulation (n  4 mice per group). Bars  100 m. C and E, Transcriptional alterations of the indicated genes in paws of
doxycycline-inducible human tumor necrosis factor  (hTNF)–transgenic mice (n  9 paws per group). Values are the mean  SEM. D and F,
Relationship between human TNF and indicated mRNAs in paws of doxycycline-inducible human TNF–transgenic mice treated for 6 weeks with
doxycycline (n  23 paws). Mean mRNA levels in untreated mice were assigned a value of 1. Osx  osterix; Coll. I  type I collagen; MMP-3 
matrix metalloproteinase 3; Cath. K  cathepsin K.   P  0.05;   P  0.01;   P  0.001;   P  0.0001.
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to occur earlier and more intensely than the activation of
skin keratinocytes. While only single cells of the epider-
mis were weakly S100A9 positive 1 week after doxycy-
cline administration, many cells of the nail root always
showed strong S100A9 staining at this time. The pattern
of arthritis and skin involvement somehow reflects a
psoriatic phenotype, although typical signs, such as
epidermal hyperproliferation, are missing.
Next, we aimed to analyze how quickly the signs
of inflammation could be recorded after doxycycline
administration. Therefore, we analyzed DIP joints as
early as 24 hours after doxycycline treatment (see http://
zmbe.uni-muenster.de/vwixler/retser.zip). The soft tis-
sue around DIP joints was already S100A9 positive at
that time, with the released soluble protein being cap-
tured by acellular structures of the connective tissue.
Ligaments and bone tissue were stained weakly, as were
also a few keratinocytes. It was striking, however, that
essentially no cell infiltrates, including S100A9-positive
cells, were present on day 1 of doxycycline administra-
tion. This did not change markedly on day 3 of doxycy-
cline administration, but from day 7 onward, numerous
infiltrating immune cells, including S100A9-positive
cells, were noted (Figures 2E and 4A) (see http://
zmbe.uni-muenster.de/vwixler/retser.zip). Taken to-
gether, these data show that the S100A9 protein is
exposed in distal phalangeal tissue very early after the
induction of TNF; it precedes the immigration of
immune cells and already reflects the early beginnings of
inflammatory activities in these tissues.
Cartilage and bone phenotype. An additional
peculiarity was the S100A9 staining of the chondrocytes
and bones of the phalanges from week 1 onward as well
as the bone-invading pannus-like tissue at later stages
(Figures 3A and 4A) (see http://zmbe.uni-muenster.
de/vwixler/retser.zip). As for other S100A9 stainings,
these also disappeared almost completely 3 weeks after
the withdrawal of doxycycline (Figure 4A). To study
whether the observed cartilage damage in DIP joints
was restricted to the loss of proteoglycans alone or was
accompanied by additional tissue loss, we analyzed
changes in expression of the articular cartilage matrix
protein type II collagen by immunohistochemistry and
qRT-PCR (Figures 5A and C). Quantification of type II
collagen staining revealed a gradual reduction in the
DIP joints during doxycycline stimulation and a quick
and significant recovery after doxycycline removal.
Along with the protein loss, the transcriptional activity
of the type II collagen gene decreased nearly 5-fold at
week 6 but recovered when doxycycline was withdrawn.
To see whether osteoblast function was impaired with
doxycycline treatment as well, we analyzed the transcrip-
tion of 2 well-established markers of osteoblast activity,
type I collagen and osterix. The mRNA levels of both
Figure 6. Bone phenotype of control (unstimulated) doxycycline-inducible human tumor necrosis factor  (TNF)–transgenic mice and
doxycycline-inducible human TNF–transgenic mice treated with doxycycline for 6 weeks. A, In vivo methylene diphosphonate (MDP)
single-photon–emission computed tomography images showing a similar distribution pattern of MDP in doxycycline-treated (n 3) and control (n
2) doxycycline-inducible human TNF–transgenic mice. B, Representative micro–computed tomography (micro-CT) images of fore paws of control
(n  2) and doxycycline-treated (n  4) doxycycline-inducible human TNF–transgenic mice. Bar  1 mm. C, Representative micro-CT images of
the first 2 distal phalanges of the middle digits. Bar  100 m. D, Cross-section of metacarpals.
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genes, and especially of type I collagen, were strongly
reduced with doxycycline stimulation, and similar to type
II collagen, they were restored when the antibiotic was
withdrawn (Figure 5C). Further, consistent with numer-
ous data showing that TNF suppresses the expression
of type I collagen and osterix (20,21), the transcript
levels of both genes showed a high inverse correlation
with the amount of induced human TNF in the organ
(Figure 5D).
Development of both PsA and RA is frequently
accompanied by bone erosion due to osteoclast activa-
tion and increased synthesis of collagenolytic protein-
ases (22,23). Morphometric analysis of tartrate-resistant
acid phosphatase (TRAP)–positive tissue in the distal
phalanges as a marker of activated osteoclasts and
monocytes showed a clear increase in TRAP expression
during the time of doxycycline treatment, and as with
other signs of TNF-mediated inflammation in this
organ, TRAP expression reverted to control levels after
removal of the antibiotic (Figure 5B). Also, the tran-
scriptional activity of TRAP, cathepsin K, and several
MMPs increased with doxycycline stimulation and de-
clined with its withdrawal (Figure 5E). An especially
high transcriptional increase was noted for MMPs 3 and
9, and mRNA levels of these genes as well as those of
cathepsin K in single animals correlated very well with
mRNA levels of human TNF (Figure 5F). Thus, in
addition to severe inflammation, our analyses of the toes
also revealed cartilage destruction and signs of bone
erosion due to altered activation of osteoblasts and
osteoclasts.
Visual inspection of in vivo SPECT images did
not reveal gross alterations of skeleton structures (Fig-
ure 6A). Therefore, we performed a comparative
micro-CT analysis of the fore paws from control and
doxycycline-treated mice to explore whether bone tissue
damage takes place in inflamed toes (Figures 6B and C).
Bones of doxycycline-treated mice, but not those of
control doxycycline-inducible human TNF–transgenic
mice, displayed clear signs of tissue damage. Especially
bones of the first 2 distal phalanges were severely
affected, exactly where the major inflammation was
always seen. However, clear signs of bone resorption
were also detectable in more distal bones (Figure 6D).
These results are consistent with data shown in Figure 5
and suggest an altered osteoblast/osteoclast homeostasis
in paws with human TNF induction.
DISCUSSION
While several TNF-transgenic mice already ex-
ist, no inducible mouse model has previously been
described. In the present study, we describe the pheno-
type of such a mouse line. We show that human TNF
expression is present in the blood, skin, and fore paws of
doxycycline-inducible human TNF–transgenic mice ex-
clusively with doxycycline administration and is reduced
to control levels as early as 1 week after doxycycline
removal. We further show that upon doxycycline stimu-
lation, doxycycline-inducible human TNF–transgenic
mice develop a wide range of abnormalities that are
characteristic of arthritis-like diseases. Inflammation of
distal phalanges accompanied cartilage and bone de-
struction and dermal inflammation. However, when
doxycycline was removed, almost all abnormalities were
reversed during the following 3 weeks. While human
TNF was expressed in many organs and reached high
levels in the blood that were comparable with those
reported in Tg197-transgenic mice (10), only the digits
and, to a lesser extent, the skin and ankles were affected
in doxycycline-inducible human TNF–transgenic mice.
We have not seen signs of inflammation in other organs,
either by macroscopic or histologic analyses. Much
higher local than systemic concentrations of human
TNF might be a reasonable explanation for this.
A major advantage of our mouse model is that
the disease is inducible and can be induced at any stage
of life, and the degree as well as the state of inflamma-
tion (acute, chronic, or batchwise) can be fine-tuned.
Further, doxycycline-inducible human TNF–transgenic
mice not yet exposed to doxycycline are vital and fertile
and can therefore be crossed, without limitations, with
other transgenic or knockout mice, and we believe that
the doxycycline-inducible human TNF–transgenic
mouse is a valuable tool for studying the intrinsic
mechanisms of TNF-mediated diseases.
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